After Covishield and Covaxin getting approved by the health ministry for the vaccination process in India, here are few other vaccine candidates.
This Zydus Cadila’s vaccine named ZyCov-D is being made on the DNA platform. Cadila has collaborated with the Department of Biotechnology for making this vaccine. DCGI has given its approval to initiate its Phase 3 clinical trials of the Covid vaccine.
This vaccine is developed by Russian Gamaleya Institute. Phases 2 and 3 of clinical trials are conducted by Dr Reddy’s Laboratories.
Serum Institution of India is developing this vaccine in collaboration with NovaVax, an American company. Phase 3 trial is under consideration.
This vaccine is by Pune-based Gennova Pharmaceuticals is supported by a seed grant under the Ind-CEPI mission of the department of biotechnology of the Union Ministry of science and technology.
The company has worked in collaboration with US’ HDT Biotech Corporation to develop the mRNA vaccine candidate. According to reports, Gennova will start its first phase of trial of its indigenous vaccine candidate by January.
Bharat Biotech’s second vaccine
Bharat Biotech is also working on another Covid vaccine in collaboration with Thomas Jefferson University, US. This vaccine is at its pre-clinical stages.
Aurobindo Pharma vaccine
Aurobindo Pharma Ltd announced its own vaccine, which uses recombinant vesicular stomatitis virus (RVSV) vector platform, through its US subsidiary.
The vaccine is being developed by Profectus BioSciences and is still in its trial phase. Aurobindo Pharma will also make and sell US-based COVAXX’s covid vaccine candidate for supply in India under a licensing deal.
Covid vaccine candidates all over the world
BNT162B2: The vaccine developed by Pfizer Inc. and BioNTech SE of US has got approval for emergency use in the vaccination process in countries such as UK, Canada, Mexico and Bahrain.
This vaccine is being developed by ImmunityBio, a privately held immunotherapy company and NantKwest, Inc. , a cell-based therapeutic company of USA. This vaccine is in its first phase of clinical trial.
This vaccine is being developed by an Italian biotechnology company ReiThera. It is based on adenovirus that infects gorilla. This vaccine is in its Phase 2 of clinical trial.
This vaccine is developed by COVAXX, a subsidiary of United Biomedical. The Phase 1 trial of this vaccine is underway and Phase 2 trial is expected to begin in the first quarter of 2021.
This is developed by a Russian biological research centre known as Vector Institute. It has registered for phase 1 trial on August 26, 2020. This vaccine got regulatory approval in Russia even though phase 3 trials were not started.
Vaxart, a California based biotech firm, is working on developing oral vaccine for Covid-19 using an adenovirus called Ad5. Its phase 1 trial is underway.